News Releases

May 2019

May 14, 2019 5/14/2019 Takeda Reports FY2018 Full Year Results and Issues FY2019 Guidance

May 9, 2019 5/9/2019 U.S. FDA Accepts Takeda’s Application for SC Formulation of Vedolizumab for Maintenance Therapy in Ulcerative Colitis

May 8, 2019 5/8/2019 TAKEDA SIMPLIFIES PORTFOLIO AND ACCELERATES DELEVERAGING THROUGH TWO DIVESTITURES

May 7, 2019 5/7/2019 Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

April 2019

April 25, 2019 4/25/2019 Revised Forecast of Consolidated Financials for FY2018 (IFRS)

April 15, 2019 4/15/2019 Takeda Announces Top-Ranked Investment Analyst Atsushi Seki to Join Takeda

April 1, 2019 4/1/2019 EMA Accepts Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Ulcerative Colitis and Crohn’s Disease

March 2019

March 26, 2019 3/26/2019 Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

March 9, 2019 3/9/2019 Vedolizumab Achieves Superior Rates of Clinical Remission vs. Adalimumab in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

・For legacy Shire information, click here